ERVW-1 and B-cell chronic lymphocytic leukemia: For the treatment of chronic lymphocytic leukemia (CLL), a study used B cells that were targeted by EVs tagged with a viral envelope protein (gp350) and transferred gp350 and CD40L to the patients’ cells, leading to an anti-CLL immune response [114].